Autonomix to present clinical study on Nerve Neurolysis at CRT 2026

Autonomix (AMIX) Medical announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies, CRT, 2026 Meeting, happening March 7-10, 2026, in Washington, DC. The abstract titled, “Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency Ablation: Clinical Feasibility And Outcomes,” will be presented during the Top Abstract Session on March 7 for Hypertension Therapies and Renal Denervation session. Dr. Cesarovic will deliver a six-minute presentation, highlighting clinical feasibility and early outcomes associated with a novel RF-based approach designed to selectively disrupt peripheral nerve activity via a transvascular approach. Autonomix’s technology is engineered to identify and target specific nerve signals, potentially enabling differentiated therapeutic precision compared to conventional ablation techniques.